Лабетузумаб говитекан

Rec. INN (наименование, зарегистрированное ВОЗ)

91668184

DB12331

1469876-18-3

immunoglobulin G1-kappa, anti-[Homo sapiens CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e)], monoclonal antibody conjugated to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan; gamma1 heavy chain (1-449) [humanized VH (Homo sapiens IGHV3-48*01 (75.30%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01, G1m17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343- 447), CHS (448-449)) (120-449)], (222-213')-disulfide with kappa light chain (1’-213’) [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (85.70%) -IGKJ1*01) [6.3.8] (1'-106') -Homo sapiens IGKC*01, Km3 (107'-213')]; dimer (228- 228":231-231")-bisdisulfide; conjugated, on an average of 6 cysteinyl, to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan (CPT-11, camptothecin-11), via a maleimide-type cleavable linker (carbonate group, 4-aminobenzyl alcohol and cathepsine-B-cleavable dipeptide Phe-Lys) and containing a triazoline group and a spacer PEG (n=8)

C₇₅H₁₀₂N₁₂O₂₄S

1587,7 г/моль

Поделиться этой страницей